A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

This study is testing new investigational drug combinations in patients with triple-negative breast cancer (TNBC) — a type of breast cancer that lacks estrogen, progesterone, and HER2 receptors — that has come back or spread after prior treatment. It is a Phase I study focused on finding the safest and most effective dose of these new treatments. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced or metastatic triple-negative breast cancer (HER2-negative and hormone receptor-negative) - Your cancer has relapsed early (within 6–12 months) after prior treatment including chemotherapy and a PARP inhibitor - You are in reasonably good overall health **You may NOT be eligible if...** - Your cancer is still potentially curable with surgery - You have not received certain required prior treatments - You have significant heart, liver, kidney, or other organ problems Talk to your doctor to see if this trial is right for you.